Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
| Autor: | Sai-Hong Ignatius Ou, Yanfei Gao, Viola W. Zhu, Kenneth A. Bauer, Joseph J. Zhao, Nicholas Syn, Shannon S. Zhang, Misako Nagasaka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Gastroenterology 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins Internal medicine ROS1 medicine Humans Cumulative incidence Gene Rearrangement business.industry Hazard ratio Receptor Protein-Tyrosine Kinases Odds ratio Protein-Tyrosine Kinases medicine.disease Pulmonary embolism 030104 developmental biology Increased risk Oncology 030220 oncology & carcinogenesis Meta-analysis Non small cell business |
| Zdroj: | Lung Cancer. 157:147-155 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2021.05.019 |
| Popis: | INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis respectively for either ALK+ or ROS1+ NSCLC patients. RESULTS We identified eight studies (766 ALK+, 143 ROS1+, 2314 non-ALK+ and non-ROS1+ NSCLC patients) for the meta-analysis. For ALK+ NSCLC, the pooled OR was 2.00 (95% CI: 1.60-2.50) for total TE (TTE) by random-effects model, 2.10 (95% CI: 1.70-2.60) for venous thromboembolism (VTE), and 1.24 (95% CI: 0.80-1.91) for arterial thromboembolism (ATE). For ROS1+ NSCLC, the pooled OR was 3.08 (95% CI: 1.95-4.86) for TTE, and 3.15 (95% CI: 1.83-5.43) for VTE. Six studies (739 ALK+, 137 ROS1+, 561 EGFR+, 714 "wildtype" NSCLC patients) were included in the time-to-event analysis. The TTE incidence rate was 17.4 (95% CI: 15.3-19.5) per 100 pateint-years for ALK+ NSCLC, and 32.1 (95% CI: 24.6-39.6) per 100 patient-years for ROS1+ NSCLC with a 50 % cumulative incidence rate at year 3 of diagnosis. HR for TTE was 2.35 (95% CI: 1.90-2.92, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect